Microvascular endothelial barrier breakdown in sepsis precedes organ failure and death in patients. We tested the hypothesis that the formation of endothelium-derived soluble vascular endothelial (VE)-cadherin fragments (sVE-cadherin) is involved in inflammation-induced endothelial barrier disruption.
Introduction
Sepsis remains the leading cause of death on non-cardiac intensive care units with mortality rates 30 -50%. 1 -3 A hallmark in the pathogenesis of sepsis and systemic inflammation is the breakdown of microcirculation, in which endothelial activation and dysfunction play a pivotal role. Endothelial dysfunction is characterized by barrier disruption with increased extravasation of fluid followed by organ dysfunction, metabolic dysbalance, and death. 3 -7 The endothelial barrier is sealed by tight and adherens junctions, in which the 120 kDa vascular endothelial (VE)-cadherin is the major transmembrane adhesion molecule of endothelial adherens junctions and thus represents a crucial determinant of endothelial barrier integrity. 8 The smallest functional unit of VE-cadherin is represented as a dimer with an intra-and extracellular domain. 9 Meanwhile it is well known that bacterial lipopolysaccharide (LPS) or pro-inflammatory cytokines that are involved in the pathogenesis of sepsis such as tumour necrosis factor-a (TNF-a) disrupt the endothelial barrier at least in part by reduced cyclic adenosine monophosphate (cAMP) levels in endothelial cells which impairs VE-cadherin-mediated adhesion. 10 -15 The crucial role of VE-cadherin-mediated adhesion in this context was underlined by experiments where inflammation-induced endothelial barrier disruption was blocked by a VE-cadherin tandem peptide that augmented VEcadherin transinteraction. 16 Interestingly, clinical data demonstrate that increased levels of VE-cadherin fragments (sVE-cadherin) in the blood of septic patients are associated with negative outcome of these patients. 17 Because usually severe sepsis is accompanied by loss of endothelial barrier functions, we hypothesized a role of VE-cadherin fragments in the pathogenesis of endothelial barrier dysfunction. Furthermore, the formation of sVE-cadherin may be a useful diagnostic marker for early detection of endothelial barrier dysfunction in sepsis. When focussing on the endothelial microenvironment in the pathogenesis of sepsis and systemic inflammation, shedding of membrane proteins is increasingly recognized. Shedding is mediated by specific disintegrins and metalloproteinases (ADAMs) and includes the release of cytokines, growth factors, chemokines, and adhesion molecules, which are mostly synthesized as transmembrane molecules by endothelial cells, leukocytes, platelets, and smooth muscle cells. 18 -20 Interestingly, it was shown that the cleavage of VE-cadherin by ADAM10 plays an important role in T-cell transmigration and may contribute to increased endothelial permeability. 21, 22 Therefore, we hypothesized that inflammation-induced breakdown of the endothelial barrier results in an increase of VE-cadherin fragments (sVE-cadherin) released from endothelial cells. We tested whether the underlying mechanism involves activation of ADAM10 and whether sVEcadherin might contribute to endothelial barrier disruption by inhibition of VE-cadherin binding. In a direct approach to test a potential clinical role of sVE-cadherin in sepsis, blood samples of patients with severe sepsis were taken and sVE-cadherin levels were compared with healthy individuals.
Methods

Test reagents
LPS from Escherichia coli O111:B4 (Sigma-Aldrich, L2630; Taufkirchen, Germany) at 100 ng/mL and TNF-a at 100 ng/mL (Biomol, Hamburg, Germany) were used to induce endothelial barrier disruption. 12, 14 To increase intracellular cAMP levels, phosphodiesterase-4-inibitor (PD-4-I) rolipram (Sigma-Aldrich) at 10 mM was used. 12, 23 GI254023X (Tocris, Bioscience R&D Systems, Wiesbaden, Germany), a potent and specific inhibitor of the VE-cadherin-specific disintegrin and metalloproteinase ADAM10, was applied at 10 mM. 21, 24 Digestion of VE-cadherin was performed using recombinant human VE-cadherin-Fc Chimera (100 ng/mL; R&D Systems; CatNo 938-VC-050) and recombinant human ADAM10 (0.269 mg/mL; R&DSystems; Wiesbaden; Germany; CatNo 936-AD-020).
Staurosporine was used at 1 mM (Sigma, CatNo S6942).
Cell culture
We used HDMEC (Promocell, Heidelberg, Germany) that were described previously to be a suitable model to study microvascular endothelial barrier regulation in vitro. 12 Cells were used from Passages 1 to 7 and grown in endothelial growth medium containing supplement mix and were passaged using Detach kit-30 (both Promocell). Culture confluency was checked by daily microscopy.
Measurement of endothelial permeability and integrity
ECIS 1600R (Applied BioPhysics, Troy, NY, USA) was used to measure the transendothelial resistance (TER) of HDMEC monolayers to assess endothelial barrier integrity as described previously. 25 Cell cultures were incubated with fresh medium in the presence or absence of LPS or TNF-a. Rolipram or GI254023X was simultaneously applied with LPS or TNF-a, respectively. Additionally, recombinant human VE-Cadherin was applied at different concentrations as indicated below.
Immunocytochemistry
Immunostaining was performed as described in detail previously. 23 HDMECs were grown to confluence on cover slips for 7 -10 days. After incubation with mediators as indicated below fixation with 2% formaldehyde and treatment with 0.1% Triton X-100, we used a polyclonal goat antihuman vascular endothelial (VE)-cadherin antibody against the C terminal end (intracellular domain of VE-cadherin) (sc6458; Santa Cruz, Heidelberg, Germany) and a mouse mAb (sc101580; Santa Cruz Heidelberg) against the N terminal end (extracellular domain of VE-cadherin) as primary antibodies (1:100 in PBS each). As secondary antibodies, we used a Cy3-labelled donkey anti-goat IgG, a Cy3-or Cy2-labelled goat anti-mouse IgG, respectively (all from Dianova, Hamburg, Germany, diluted 1:600 in PBS). All experiments were performed in triplicates for each condition.
Measurement of soluble VE-cadherin
For detection of sVE-cadherin in cell culture supernatants, western blotting and ELISA-based analyses were performed. For measurements of sVEcadherin in western blots, acetone precipitation of proteins was performed as described previously. 26 In brief, seven-fold amount of acetone (2208C)
was slowly added to cell culture supernatants and kept at 2808C over night. Then supernatants were centrifuged at 10 000 g for 15 min, and acetone was gently removed. Thereafter, 50 mL of lysis buffer was added and SDS gel electrophoresis was performed.
Western blotting
SDS-PAGE and immunoblotting were carried out, as reported previously.
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The antibodies against VE-cadherin and b-actin (Sigma) were used at a dilution of 1:500. The monoclonal ADAM-10 antibody (sc48400; Santa Cruz Biotechnology, Heidelberg, Germany) was used at a dilution of 1:100. A caspase-3 immunoblot was performed using a Cleaved Caspase-3 (Asp175) antibody (Cell Signaling, Wiesbaden, Germany; CatNo 9661) at a dilution of 1:600 as primary antibody. As secondary antibodies, the respective horseradish peroxidase-labelled goat anti-mouse IgG, goat anti-rabbit IgG, or donkey anti-goat IgG (Santa Cruz) were used (1:3000 in PBS). Bound immunoglobulins were visualized by the enhanced chemiluminescence technique (ECL, Amersham, Munich, Germany).
Cell viability assay
For measuring cell viability CellTiter-Glo w 2.0 Assay (Promega, Madison, WI, USA; CatNo G9241), a luminescence-based cell viability assay was used. The number of viable cells in culture is determined by quantification of the amount of ATP present. The experimental set-up was designed and executed according to the manufacturer's protocol. In brief, cells were grown on opaque-walled multiwall plates, CellTiter-Glo w 2.0 Reagent was added, and luminescence signal was measured. The luminescence signal is proportional to the amount of ATP present; the amount of ATP is directly proportional to the number of viable cells present in culture. Data were normalized to the controls of each experiment.
Enzyme-linked immunosorbent assay
ELISA-based quantification of soluble VE-cadherin in cell culture supernatants and patients' blood samples was performed by using human VEcadherin ELISA (DCADV0; R&D Systems,Wiesbaden-Nordenstadt, Germany) according to manufacturer's instructions. According to the manufacturer, the antibody in this ELISA recognizes epitopes between Asp48 and Gln593 which correspond to the extracellular domain of VE-cadherin. In cell culture experiments, concentrations of sVE-cadherin (in ng/mL) from each Soluble VE-cadherin in sepsis control experiment were set to 100% and compared with sVE-cadherin levels of cell culture supernatants treated as indicated above. Stain, Thermo Scientific, Waltham, USA; CatNo 24615). After electrophoresis, gel was placed in a clean glass tray and stained for 2 h. Destaining with aqua dest was done overnight. Thereafter, western blotting was performed as described above.
Digest and analysis of recombinant VE-cadherin
The potential cleavage sites of ADAM10 and the cleavage products were analysed via MSMS mass spectrometry. For analysis, the relevant protein bands were excised out of the coomassie-stained SDS gel and sent to Proteome Factory (Berlin, Germany) for analysis ( Figure 4C -G).
Atomic force microscopy measurements with recombinant VE-cadherin-Fc
Recombinant VE-cadherin-Fc was eucaryotically expressed in stably transfected Chinese hamster ovary (CHO) cells (kindly supplied by Vestweber et al. 27 ) and purified as described previously. 16 A Nanowizard III (JPK Instruments, Berlin, Germany) AFM set-up was applied to measure binding events of single VE-cadherin-Fc molecules as outlined previously in detail. 28 In brief, interaction of recombinant VE-cadherin was characterized by force -distance measurements of VE-cadherin-Fc coupled via flexible linkers to Si 3 N 4 tips of the cantilever (MLCT, Bruker, Mannheim, Germany) and freshly cleaved mica plates (SPI supplies, West Chester, USA) using polyethylene glycol (PEG) spacers containing an amino-reactive crosslinker group at one end and a thiol-reactive group at the other end. 16, 29 Binding events were detected in HBSS buffer by force -distance cycles at amplitudes of 300 nm and 1 Hz frequency yielding continuous trace and retrace velocities of 1000 nm s
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. For every condition, 1000 force-distance cycles were recorded and each condition was repeated with new cantilever and mica preparations, n ¼ 3 -4 times. To test whether sVE-cadherin affected VE-cadherin transinteraction, cell culture supernatant containing sVE-cadherin was applied. Additionally, recombinant human VE-cadherin was used at 50 and 100 ng/mL. Cell culture supernatant containing no sVEcadherin and supernatant from which sVE-cadherin was depleted after incubation of cells with TNF-a were used as controls. Depletion of sVEcadherin was carried out using an immunoprecipitation protocol (GE Healthcare; CatNo 17-6002-35) according to manufacturer's protocol. In brief, supernatants of HDMEC containing sVE-cadherin after 4 h incubation of TNF-a were incubated over night at 48C with 1 mg VE-cadherin antibody (R&D System, CatNo MAB 9381) to couple sVE-cadherin in the supernatant to the antibody. The originated ICs were precipitated with an equal mixture of Protein A and G sepharose. After centrifugation, the supernatant was used for AFM experiments. Successful depletion of sVEcadherin from the supernatant was confirmed by western blot analyses.
Patients' blood samples
As a proof of principle, blood samples of seven patients suffering from severe sepsis or septic shock with loss of microvascular dysfunction indicated by generalized skin oedema and excessive needs of volume therapy were collected to evaluate a possible clinical role of sVE-cadherin after ethical approval (University of Würzburg proposal number 147/12). Informed consent was given prior to the inclusion of the patients in the study. The studies conformed to the declaration of Helsinki. Additionally, blood samples from 11 healthy volunteers were collected. Concentrations of sVE-cadherin in blood samples were measured using an ELISA-based system as described above. Due to massive and different infusion requirements, sVE-cadherin levels were adapted to serum albumin to enable a reliable comparison of sVE-cadherin levels between healthy and critically ill patients [sVE-cadherin corrected ¼ (normal serum albumin [4.5 g/dL]/actual serum albumin)*sVEcadherin]. Patients' characteristics are presented in Table 1 .
Statistical analysis
Values are expressed as mean + S.E.M. Statistical analyses were performed using GraphPad Prism w 6.0d. For parametric parameters, possible differences were assessed with t-test or ANOVA followed by Tukey test. For non-parametric data, Kruskal -Wallis following Dunn's post-test or Mann -Whitney U-test were used for significant differences. The tests used for respective experiments are indicated in the figure legends. Statistical significance is assumed for P , 0.05.
Results
TNF-a induced loss of VE-cadherin at the cell borders in immunostaining and increased levels of VE-cadherin fragments in western blots
In blotting. The western blot of the supernatant was incubated with the antibody directed against the extracellular domain and showed augmented VE-cadherin fragments with a double band at 90 kDa beginning after 2 h of TNF-a incubation which was more pronounced after 4 h ( Figure 1B , upper blot). In contrast, when western blots of the supernatants were incubated with an antibody directed against the intracellular domain, we detected no bands ( Figure 1B , middle blot). When performing western blots with whole cell lysates using the same antibody directed against the intracellular domain of VE-cadherin showed equal amounts of VE-cadherin under the different experimental conditions.
ELISA-based measurements of increased sVE-cadherin correlated with endothelial barrier breakdown
We used an ELISA-based system to measure the amount of soluble VEcadherin in the cell culture supernatants following incubation with TNF-a or LPS, respectively. We observed that incubation with TNF-a or LPS showed a significant increase of sVE-cadherin in supernatants in a time-dependent manner ( Figure 2A and B). After 1 and 2 h of TNF-a application, the amount of sVE-cadherin was slightly elevated to 1.07 + 0. Figure 2B ). Application of phosphodiesterase-4-inhibitor rolipram which is known to block inflammation-induced endothelial barrier breakdown 30 attenuated the release of sVE-cadherin into cell culture supernatants. Under control conditions, VE-cadherin was regularly distributed at cell borders (Aa). Incubation with TNF-a for 1 h altered VE-cadherin immunostaining to an irregular distribution (Ab). After 2 and 4 h of TNF-a incubation, this effect was augmented, VE-cadherin was fragmented, and intercellular gaps were observed (arrows in Ac -d); experiment shown is representative for n . 5 experiments; scale bar is 20 mm. (B and D) western blot analyses of soluble VE-cadherin (sVE-cadherin, 90 kDa) in supernatant of HDMEC monolayer revealed an increasing amount of sVE-cadherin in a time-dependent manner after TNF-a incubation compared with control (upper blot). Incubation of the western blot of cell culture supernatant with an antibody against the intracellular domain of VE-cadherin did not show any specific band (middle blot). Western blots of whole cell lysates using the same antibody directed against the intracellular domain of VE-cadherin revealed no alterations (lower blot). (C and E) Quantifications of all experiments of the upper and lower western blots are shown on the right side without significant differences. For statistical analysis, a Mann-Whitney rank sum test was used. Western blots shown are representative for n . 4 experiments.
Similarly, rolipram attenuated LPS-induced sVE-cadherin release ( Figure 2B ). Rolipram alone did not affect levels of sVE-cadherin compared with controls ( Figure 2A) .
To demonstrate the temporal correlation of TNF-a and LPS-induced formation of sVE-cadherin and endothelial barrier disruption, we measured TER ( Figure 2C and D) . The incubation of HDMEC monolayers with TNF-a ( Figure 2C ) and LPS ( Figure 2D ) showed significantly decreased TER compared with controls beginning after 3 h of TNF-a and 5 h of LPS incubation, respectively. As demonstrated previously, 12,13 application of rolipram attenuated the TNF-a-and LPS-induced loss of endothelial barrier functions.
In summary, these experiments demonstrated that the release of sVE-cadherin is closely associated with breakdown of endothelial barrier properties.
To exclude that TNF-a-mediated increase of sVE-cadherin in cell culture supernatants was due to increased cell death, we performed a cell viability assay and western blots against cleaved caspase-3 to test for apoptosis following TNF-a application. In western blot analyses, we detected no specific bands for cleaved caspase-3 after application of TNF-a at 1, 2, 4, 8 while application of staurosporine which served as a positive control to induce apoptosis showed strong bands at these time points (Figure 3A-D) . In the luminescence-based cell viability assay, we found no significant alterations of cell viability following application of TNF-a at all time points. In cells that were incubated with staurosporine, we found a significant reduction of cell viability after 24 h ( Figure 3E ).
ADAM10 inhibitor GI254023X reduced sVE-cadherin levels and blocked inflammation-induced breakdown of endothelial barrier functions
Application of TNF-a or LPS for 4 h did not significantly alter total protein amounts of ADAM10 in western blot analyses, although the ADAM10-specific bands appeared slightly increased following TNF-a or LPS incubation ( Figure 4A and B) . This was unchanged when TNF-a or LPS was incubated together with rolipram. Next, we aimed to confirm whether ADAM10 activity would result in the formation of sVE-cadherin and therefore we incubated recombinant ADAM10 together with recombinant VE-cadherin. In the coomassiestained SDS gel, we found one band at 130 kDa and one band at 65 kDa which corresponded to VE-cadherin and ADAM10 in the lanes where only recombinant VE-cadherin or ADAM10 was applied, respectively ( Figure 4C ). After the digest of VE-cadherin with ADAM10, two additional bands were visible in coomassie-stained gel, i.e. at 110 kDa and one faint band 90 kDa (indicated by the arrows in Figure 4C) . Incubation of the gel with an antibody directed against the extracellular domain of VE-cadherin resulted in a western blot signal at 130 kDa as well as at 110 and 90 kDa which correspond to sVE-cadherin (arrow in Figure 4D ). In control experiments, incubation of the gel with an ADAM10 antibody showed a single band at 65 kDa ( Figure 4E) .
To further characterize the cleavage product and the potential cleavage sites of ADAM10, the bands at 110 and 90 kDa were excised out of the coomassie-stained SDS gel and sent to Proteome Factory to perform MSMS mass spectrometry. As exemplified in Figure 4F -H, only peptides up to 452 amino acids (aa) were seen and one peptide at 503 -530 aa. These sequences correspond to EC1-5 of human VEcadherin as the cleavage product of ADAM10. Furthermore, these analyses indicated that ADAM10 cleaves VE-cadherin at 452-500 aa. Additionally, two other cleavage sites can be postulated, i.e. one at 80-127aa and the other at 160-175aa.
To verify that ADAM10 plays a critical role in the formation of sVEcadherin in our in vitro system, we next performed experiments using the specific ADAM10 inhibitor GI254023X as reported previously. ELISA-based measurements of sVE-cadherin after incubation with GI254023X followed by application of TNF-a or LPS, respectively, showed that this approach blocked formation of sVE-cadherin (Figure 5Aa, b) . While TNF-a alone significantly augmented sVEcadherin to 1.31 + 0.05-fold controls after 4 h, TNF-a + GI254023X dramatically reduced sVE-cadherin levels of 0.18 + 0.01-fold of controls after 4 h (Figure 5Aa) . Similarly, LPS augmented sVE-cadherin levels of 1.32 + 0.06-fold of controls, whereas LPS + GI254023X resulted in reduced sVE-cadherin levels of 0.17 + 0.01-fold of controls (Figure 5Ab) . Application of GI254023X alone resulted in sVE-cadherin levels of 0.63 + 0.65-fold of controls (Figure 5Aa) . Soluble VE-cadherin in sepsis Interestingly, measurements of TER revealed that incubation with GI254023X blocked TNF-a-induced drop of TER and even resulted in a transient increase of TER compared with control ( Figure 5Ac) . Similarly, while LPS alone significantly decreased TER, the LPS-induced drop of TER was diminished by incubation with GI254023X. Compared with controls, no differences were observed (Figure 5Ad) . Application of GI254023X alone did not change TER compared with controls ( Figure 5Ac) .
Immunostaining of the extracellular domain of VE-cadherin following TNF-a or LPS application for 4 h resulted in VE-cadherin fragmentation and loss of VE-cadherin staining at some parts of the cell borders (Figure 5Bb,e) , which was abolished by co-incubation of TNF-a or LPS together with GI254023X (Figure 5Bc,f) .
Taken together, these experiments showed that formation of sVEcadherin is dependent on ADAM10 activity. Importantly, the data indicate that conditions in which sVE-cadherin is not present results in intact endothelial barrier functions even in the presence of TNF-a or LPS.
VE-cadherin binding was blocked by sVE-cadherin as revealed by atomic force microscopy and TER measurements
Because reduced sVE-cadherin formation by GI254023X resulted in attenuation of inflammation-induced loss of endothelial barrier functions, we tested the hypothesis that sVE-cadherin may contribute to endothelial barrier breakdown by interfering VE-cadherin interaction. Therefore, we performed atomic force microscopy (AFM). In a cellfree system, binding frequencies of VE-cadherin-Fc fusion proteins covalently coupled to the tip and plate of the AFM via flexible PEG-linker were detected by performing force -distance cycles. The molecules were brought into contact and released by repeated downward (trace) and upward movements (retrace) of the AFM tip and the forces acting on the tip were constantly sampled. During upward movement, a downward deflection of the cantilever occurred if plate-and tip-bound VE-cadherin molecules underwent specific binding. After reaching a critical force, the bond broke and the cantilever jumped back to the neutral position. The number of these unbinding events was divided by the total number of force curves yielding the binding frequency. As a positive control, Ca 2+ depletion by using EGTA reduced binding activity to 21.84 + 3.95%. As a negative control, cell culture medium containing no sVE-cadherin did not change binding activity (89.5 + 9.08%) ( Figure 6A ). Application of cell culture supernatant from endothelial monolayers incubated with TNF-a for 4 h containing sVEcadherin resulted in significantly reduced binding activity (32.26 + 4.36% of controls). In contrast, supernatant from endothelial monolayers incubated with TNF-a from which sVE-cadherin had been depleted did not change binding activity (79.28 + 12.98% of controls). These results indicated that sVE-cadherin in the supernatant interferes with VE-cadherin interaction. To further confirm this observation, we used recombinant VE-cadherin (rVE-cadherin) that contains the extracellular domains as outlined above at different doses in AFM measurements. We chose a concentration of 50 ng/mL that was found to be present in cell culture supernatants in response to incubation with TNF-a. Additionally, we used 100 ng/mL rVE-cadherin to test whether changes in binding activities were dose dependent. We found that both concentrations led to a significant reduction of binding activity to 44.99 + 3.95% of controls for 50 ng/mL rVE-cadherin and to 33.48 + 2.64% of controls for 100 ng/mL rVE-cadherin without significant differences between these groups.
Next we applied rVE-cadherin to endothelial monolayers at 25, 50, and 100 ng/mL and performed TER measurements and immunostaining for VE-cadherin ( Figure 6B and C) . We found that application of 25 ng/mL rVE-cadherin only showed a slight but not significant reduction of TER, while 50 ng/mL rVE-cadherin led a significant reduction of TER beginning after 15 h. Application of 100 ng/mL rVE-cadherin induced a significant loss of TER beginning after 3 h to 35.74 + 3.37% of controls after 24 h of measurements. In immunostaining of VEcadherin that was performed after 24 h of incubation with rVE-cadherin, effects were also obvious since the application of 50 ng/mL rVE-cadherin ( Figure 6C ) resulted in strongly irregular staining patterns and intercellular gap formation when compared to controls.
In summary, these data demonstrated that sVE-cadherin interferes with VE-cadherin interaction which can be mimicked by application of rVE-cadherin in AFM measurements. Incubation of rVE-cadherin affects endothelial barrier properties and VE-cadherin integrity in a dosedependent manner.
sVE-cadherin was augmented in patients with severe sepsis
After ethical approval, blood samples of 7 patients with severe sepsis were collected and the concentration of sVE-cadherin was correlated with the severity of illness and need for volume resuscitation. Details on the clinical parameters of the patients included in the analysis are shown in Table 1 . The sVE-cadherin levels were compared with blood samples of 11 healthy volunteers ( Figure 7 ). In patients with severe sepsis, a massive infusion requirement was required in all seven cases, which ranged between 5 and 20 L/24 h for cardiovascular stabilization. Therefore, sVE-cadherin levels were associated with decreased serum albumin, which served as a factor for plasma dilution to enable interindividual comparison of sVE-cadherin levels (sVE-cadherin corrected). According to volume resuscitation and loss of microvascular barrier functions, albumin levels decreased significantly during septic inflammation. Corrected sVE-cadherin in the healthy population amounted 2609 + 168 ng/mL. In patients with severe sepsis corrected sVEcadherin amounted 5047 + 603 ng/mL and was significantly increased compared with the healthy population ( Figure 7) . In those patients who recovered (n ¼ 6), we found that in the beginning of the recovery phase sVE-cadherin was reduced to 78.40 + 7.43% of the levels measured in severe sepsis. Therefore, it could be figured out that levels of sVE-cadherin increased with development of SIRS/sepsis and decreased when recovery of patients was observed.
Discussion
Impaired microvascular endothelial barrier function in sepsis significantly contributes to organ dysfunction and death. 4 Currently, there is no appropriate therapy and no endothelium-specific biomarker for the early diagnosis of endothelial barrier disruption. The present study extents our previous investigations and shows that inflammation-induced endothelial barrier disruption is associated with formation of sVE-cadherin. This was blocked by phosphodiesterase-4-inhibitor rolipram and ADAM10 inhibitor GI254023X which both abrogated endothelial barrier breakdown. Digestion experiments using recombinant VE-cadherin and ADAM10 following spectrometry confirmed that the extracellular domain is the cleavage product and showed the cleavage sites of ADAM10. As revealed by AFM experiments, sVE-cadherin interfered with VE-cadherin interaction suggesting that sVE-cadherin contributes AFM was performed using cell culture medium without sVE-cadherin and cell culture supernatant after 4 h of incubation with TNF-a containing sVEcadherin. EGTA to remove Ca 2+ and supernatant that was depleted from sVE-cadherin served as a negative control. rVE-cadherin was used at 50 and 100 ng/mL. For each measurement, 500 force curves were measured and the frequency of binding events was determined. Soluble VE-cadherin in sepsis to endothelial barrier disruption in inflammation which points to a novel pathophysiological mechanism in this context. The relevance of this observation was confirmed when recombinant VE-cadherin containing the extracellular domain led to endothelial barrier disruption in a dosedependent manner in HDMEC monolayers. The presence of elevated sVE-cadherin in patients with severe sepsis suggests a potential clinical relevance of these observations.
Inflammation-induced endothelial barrier breakdown led to a significant release of sVE-cadherin
Incubation of endothelial monolayers with TNF-a or LPS resulted in endothelial barrier disruption, which was in close temporal correlation with a significant increase of sVE-cadherin in cell culture supernatants as demonstrated by western blotting and ELISA-based measurements. Western blot analyses revealed that sVE-cadherin fragments were predominately found at 90 kDa. Based on the size and immunoreactivity of these fragments, it can be assumed that they correspond to the full length of the extracellular domain of VE-cadherin. 31 This assumption is firstly supported by our analyses in which spectrometry of the cleavage products confirmed the presence of the extracellular domains as a result of VE-cadherin cleavage and secondly underlined by the fact that the antibody directed against the intracellular domain showed no signal in the western blot of cell culture supernatants. Previously, sVEcadherin was shown to occur in patients with RA, i.e. under conditions of chronic inflammation and also in patients with severe sepsis and poor outcome. 17, 32 However, a direct correlation between inflammation-induced endothelial barrier breakdown by sepsisrelevant stimuli and sVE-cadherin release has not been reported to date. Rather, it has previously been observed that cleavage of VEcadherin occurs in the context of endothelial cell apoptosis. 33 According to our experiments, sVE-cadherin in cell culture supernatants is augmented long before significant TNF-a-induced apoptosis or cell death can be detected, i.e. at the beginning of endothelial barrier disruption. The fact that relevant cell death did not occur under our present experimental conditions conforms to our previous studies.
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This is further supported by an observation of Schulz and co-workers where thrombin, which is known to augment endothelial permeability in vitro also led to increased sVE-cadherin in culture supernatants. 21 However, in contrast to the observations made for thrombin, the total amount of VE-cadherin, which was detected by an antibody against the intracellular domain, was not affected by TNF-a application, which also conforms to our previous investigations. 13 
Formation of sVE-cadherin is blocked by inhibition of phosphodiesterase-4 and ADAM10
There is a large body of evidence that cAMP increasing agents such as phosphodiesterase-4-inhibitors attenuate inflammation-induced endothelial barrier disruption in vitro and in vivo. 12,13,34 -37 Therefore, we decided to apply the phosphodiesterase-4 inhibitor rolipram to test whether a barrier-stabilizing agent may block formation of sVEcadherin. Interestingly, sVE-cadherin levels were even significantly decreased compared with controls. At these time points, TER measurements of rolipram-treated endothelial monolayers were even higher than in controls which further supports the notion that the amount of sVE-cadherin and endothelial barrier properties show an inverse correlation. In general, barrier-stabilizing effects of increased cAMP levels are thought to be mediated via Rac1-mediated strengthening of the cortical actin belt leading to increased VE-cadherin-mediated adhesion. 30 Apart from this mechanism it is also conceivable that phosphodiesterase-4 inhibition modulates other mechanisms directly involved in the formation of sVE-cadherin. In principle, this may occur by interaction with Src kinase activation and tyrosine kinase activation, which have both been demonstrated previously to participate in the formation of sVE-cadherin. 32 In an approach to address the mechanism underlying sVE-cadherin formation, we focused on the process of shedding. In general, inflammatory stimuli lead to a release of soluble variants of cytokines, chemokines, growth factors, and adhesion molecules, which are synthesized as transmembrane proteins by vascular tissue, platelets, and leukocytes. This process of shedding is caused by limited proteolysis. 18, 38 In the context of sVE-cadherin formation, Schulz et al. 21 described that ADAM10-mediated cleavage of the extracellular domain of VEcadherin is induced by thrombin, Ca 2+ influx, or apoptosis. Furthermore, an up-regulation of ADAM10 in endothelial cells was shown in the setting of inflammation. 38 This, however, was not the case in our present experiments where we observed only a slight but not significant increase of the ADAM10-specific bands in western blot analyses. This could be explained by the fact that cultured endothelial cells display an inflamed phenotype also under resting conditions. 39 However, because application of the ADAM10-specific inhibitor GI254023X completely blocked both sVE-cadherin formation and breakdown of inflammation-induced endothelial barrier functions, activation of ADAM10 rather than its up-regulation appears to play the dominant role. Furthermore, rolipram application did not result in downregulation of ADAM10 but may have interfered with its activation by yet unknown mechanisms. In this context, it has been suggested previously that G-protein-coupled receptors (GPCR) may influence sheddase activity via various mechanisms including cAMP signalling. 40 To further verify the importance of ADAM10-mediated cleavage, we digested recombinant VE-cadherin and recombinant ADAM10 which resulted in cleavage products which were comparable in size to the products we found in cell culture supernatants following application of inflammatory stimuli. The spectrometry suggested several cleavage sites, which explains the presence of a double band in the digestion experiments as well as in the cell culture supernatants. Thus, the present study for the first time suggests the specific VE-cadherin cleavage sites of ADAM10.
sVE-cadherin may interfere with VE-cadherin binding
An interesting and remarkable result was that endothelial barrier disruption and formation of sVE-cadherin did not only show a temporal correlation. Rather, inhibition of the formation of sVE-cadherin abrogated TNF-a-and LPS-induced loss of endothelial barrier functions. This led to the hypothesis that sVE-cadherin may contribute to endothelial barrier disruption which was further corroborated by AFM measurements in which cell culture supernatants containing sVE-cadherin blocked VE-cadherin binding. Importantly, depletion of the cell culture supernatant from sVE-cadherin did not lead to alterations of VEcadherin binding. Furthermore application of recombinant VE-cadherin (which contains the extracellular domain) at doses found in the cell culture supernatant also blocked VE-cadherin binding in the AFM experiments. The inhibition of VE-cadherin interaction by sVE-cadherin may contribute to a novel pathophysiological mechanism of endothelial barrier breakdown in inflammation. This hypothesis was confirmed by experiments in which application of recombinant VE-cadherin resulted in loss TER in a dose-dependent manner. Furthermore, these functional measurements were paralleled by changes of VE-cadherin staining and intercellular gap formation. The importance of VE-cadherin interaction in this context is underlined by a previous study where inflammation-induced endothelial barrier disruption was blocked by a VE-cadherin tandem peptide that augmented VE-cadherin binding. 16 Similarly, antibodies directed against the extracellular domain of VEcadherin were also shown to disrupt the endothelial barrier. 41 Based on all these observations, it is feasible that the formation of sVEcadherin may directly contribute to inflammation-induced disruption of the endothelial barrier by interfering VE-cadherin interaction. Although the relative contribution of sVE-cadherin to the loss of microvascular barrier functions in sepsis remains unclear at present, inhibition of sVE-cadherin formation may be an interesting novel target for therapeutic efforts to stabilize endothelial barrier functions.
4.4 Increased sVE-cadherin levels in patients correlated with severe sepsis and microvascular leakage
In a direct attempt to test a potential clinical relevance of our in vitro observations, we investigated sVE-cadherin levels of patients with severe sepsis and healthy individuals. Although the number of patients investigated was low, a significant increase of sVE-cadherin in sepsis was evident. This observation is supported by a previous study where enhanced levels of sVE-cadherin in patients with severe sepsis were associated with poor outcome. 17 Here we found that increased sVEcadherin levels were strongly associated with loss of microvascular barrier functions as revealed by the need of massive volume resuscitation. This led to extensive dilution effects, which initially made the comparison of sVE-cadherin with septic and healthy individuals difficult. Therefore, we decided to use albumin concentrations as an indicator for plasma volume dilution 42 and calculated sVE-cadherin based on the actual albumin parameters at each time point blood samples were taken. This approach may bear several limitations in patients, but it must be emphasized that these first data of individual patients must not be interpreted as a complete clinical trial. Nonetheless, sVEcadherin appears to play a role in sepsis and bears the potential to get a clinical marker for early detection of loss of microvascular barrier functions in sepsis. This hypothesis, however, must be investigated in a systematic clinical trial, which will be subject of future studies.
Conclusion
Taken together, our data show for the first time that sVE-cadherin is involved in and contributes to endothelial barrier dysfunction caused by sepsis-relevant mediators such as LPS and TNF-a. A clinical relevance of this observation can be carefully assumed by the presence of augmented sVE-cadherin in patients with severe sepsis.
